There are many provocative parallels with the autoantibodies in MG/thymoma patients [10,11]: their high titres at diagnosis against a similar range of IFN-α subtypes, their protracted persistence—despite immunosuppressive therapy for the MG ([11]; Figure 1A), and the constancy of their IFN-α subtype preferences ([11]; Figure 2). The gene discussed is IFNA1; the disease is myasthenia gravis.